Free Trial

Spruce Biosciences (SPRB) Competitors

Spruce Biosciences logo
$0.10 -0.01 (-5.66%)
As of 07/17/2025 03:51 PM Eastern

SPRB vs. DRRX, LPCN, PMN, GELS, ASBP, ALLR, MTEX, ATHA, FLGC, and EDSA

Should you be buying Spruce Biosciences stock or one of its competitors? The main competitors of Spruce Biosciences include DURECT (DRRX), Lipocine (LPCN), Promis Neurosciences (PMN), Gelteq (GELS), Aspire Biopharma (ASBP), Allarity Therapeutics (ALLR), Mannatech (MTEX), Athira Pharma (ATHA), Flora Growth (FLGC), and Edesa Biotech (EDSA). These companies are all part of the "pharmaceutical products" industry.

Spruce Biosciences vs. Its Competitors

Spruce Biosciences (NASDAQ:SPRB) and DURECT (NASDAQ:DRRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability, earnings and media sentiment.

91.7% of Spruce Biosciences shares are owned by institutional investors. Comparatively, 28.0% of DURECT shares are owned by institutional investors. 6.9% of Spruce Biosciences shares are owned by company insiders. Comparatively, 3.2% of DURECT shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

DURECT has a net margin of -91.54% compared to Spruce Biosciences' net margin of -555.23%. Spruce Biosciences' return on equity of -62.10% beat DURECT's return on equity.

Company Net Margins Return on Equity Return on Assets
Spruce Biosciences-555.23% -62.10% -47.49%
DURECT -91.54%-267.36%-64.00%

Spruce Biosciences has a beta of 2.4, indicating that its stock price is 140% more volatile than the S&P 500. Comparatively, DURECT has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500.

Spruce Biosciences currently has a consensus target price of $1.75, suggesting a potential upside of 1,742.11%. Given Spruce Biosciences' higher probable upside, equities research analysts clearly believe Spruce Biosciences is more favorable than DURECT.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Spruce Biosciences
0 Sell rating(s)
6 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
DURECT
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, DURECT's average media sentiment score of 1.87 beat Spruce Biosciences' score of 0.00 indicating that DURECT is being referred to more favorably in the news media.

Company Overall Sentiment
Spruce Biosciences Neutral
DURECT Very Positive

DURECT has lower revenue, but higher earnings than Spruce Biosciences. DURECT is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spruce Biosciences$4.91M0.82-$47.92M-$1.32-0.07
DURECT$2.03M8.01-$8.32M-$0.15-3.49

Summary

Spruce Biosciences beats DURECT on 8 of the 13 factors compared between the two stocks.

Get Spruce Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for SPRB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SPRB vs. The Competition

MetricSpruce BiosciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$4.01M$761.07M$5.57B$9.34B
Dividend YieldN/A4.84%3.80%4.06%
P/E Ratio-0.101.3928.1019.86
Price / Sales0.8225.51441.4199.92
Price / CashN/A19.5635.8457.94
Price / Book0.056.728.265.67
Net Income-$47.92M-$4.32M$3.24B$257.80M
7 Day PerformanceN/A-0.31%1.48%1.87%
1 Month PerformanceN/A1.39%8.07%10.92%
1 Year PerformanceN/A1.51%30.29%18.51%

Spruce Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SPRB
Spruce Biosciences
2.064 of 5 stars
$0.10
-5.7%
$1.75
+1,742.1%
-83.1%$4.01M$4.91M-0.1020Gap Up
DRRX
DURECT
1.0789 of 5 stars
$0.56
-10.5%
N/A-63.6%$17.39M$1.86M-3.7380Positive News
Gap Down
LPCN
Lipocine
3.0569 of 5 stars
$3.20
-2.1%
$9.00
+181.3%
-50.3%$17.12M$3.67M-3.1410
PMN
Promis Neurosciences
3.1626 of 5 stars
$0.52
+33.2%
$4.33
+733.3%
-78.1%$17.00MN/A-10.405News Coverage
Analyst Revision
Gap Down
High Trading Volume
GELS
Gelteq
N/A$1.76
-2.8%
N/AN/A$16.61M$100K0.00N/ANews Coverage
Gap Down
ASBP
Aspire Biopharma
N/A$0.33
+0.3%
N/AN/A$16.39MN/A0.00N/APositive News
ALLR
Allarity Therapeutics
0.6499 of 5 stars
$1.05
+4.0%
N/A-83.7%$15.83MN/A0.0010Positive News
MTEX
Mannatech
1.2354 of 5 stars
$8.31
-2.2%
N/A+12.3%$15.80M$117.87M-83.14250
ATHA
Athira Pharma
3.7738 of 5 stars
$0.40
-7.5%
$11.25
+2,696.4%
-88.4%$15.71MN/A-0.1940Positive News
FLGC
Flora Growth
2.5086 of 5 stars
$0.69
+0.6%
$4.00
+480.6%
-42.6%$15.55M$53.26M-0.70280Positive News
Gap Up
EDSA
Edesa Biotech
2.214 of 5 stars
$2.20
+5.3%
$5.00
+127.3%
-49.5%$15.44MN/A-1.3820Positive News
Gap Up

Related Companies and Tools


This page (NASDAQ:SPRB) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners